1) ~(131)I ablation therapy
131I去除治疗
2) ablative therapy
去除治疗
1.
Objective:To evaluate whether an 185MBq diagnostic dose of 131 I produces a visually apparent stunning effect 72h before 131I ablative therapy with post-thyroidectomy patients for differentiated thyroid carcinoma.
结论 :13 1I去除治疗前 72h进行 185MBq的13 1I全身诊断性显像与甲状腺组织顿抑无关 ,可以有效地应
3) 131I therapy
131I治疗
1.
Objective To study the value of TSAb detection for hypothyroidism after in 131I therapy on hyperthyreosis.
目的探讨131I治疗甲亢患者后发生甲状腺功能减退症与TSAb、MCA的关系。
2.
Objective To determine the relationgship between the serum levels of Tg and TgAb by reviewing the results of patients with differentiated thyroid cancer(DTC) before every 131I therapy.
方法:DTC患者141例,首次131I治疗前检查128人次,重复治疗前检查共计120人次,按Tg水平分为5组,比较各组间TgAb阳性率。
3.
To investigate dynamic change of serum receptor and antibody of thyrotrophic antibody(TRAb) and its prognosis value after a one-off successful therapy on Graves disease with 131I,257 Graves disease patients were treated with one dose of 131I therapy.
分析Graves病131I治疗一次性成功后,患者血清促甲状腺激素受体抗体(TRAb)的动态变化规律及其预后价值。
4) 131I Treatment
131I治疗
1.
To explore the immune effect of fufangjiakang tablets(FJT) on the treatment of Graves disease with 131I by observing the changes of serum TGAb,TMAb and TRAb levels before or after 131I treatment,121 patients with Graves disease were divided into two groups,58 patients treated with 131I alone as control group and 61 patients treated with 131I combined and FJT as research group.
通过观察131I治疗前后Graves病(GD)患者TGAb、TMAb及TRAb浓度变化,探讨复方甲亢片配合131I治疗对GD患者的免疫功能的影响。
2.
To investigate immunological function change in Graves disease(GD) patients with hypothyroidism within one year after 131I treatment,and evaluate the relationship between the 131I theatment and autoimmune thyroid disease.
探讨131I治疗后一年内GD患者甲减的免疫功能状态的改变。
3.
Conclusion: Thyroid cancer patients should be performed postoperative 131I treatment, and monitored by SPECT imaging.
目的:探讨SPECT显像对131I治疗分化型甲状腺癌的价值。
5) ~(131)I treatment
131I治疗
1.
To explore the value of serum thyroperoxidase antibody (TPOAb) dynamic change on the therapeutic effect and prognostic assessment of the~(131)I treatment patients with GD,152 outpatients were treated with ~(131)I.
探讨Graves病131I治疗过程中,血清TPOAb动态变化对治疗效果及预后的评判价值。
2.
Objective To compare the surgical resection+T_(4) inhibition therapy and surgical resection+~(131)I+T_(4)inhibition therapy for differentiated thyroid cancer(DTC) in survival rate and recurrence rate,and to prove the necessity of postoperative ~(131)I treatment.
目的比较分化型甲状腺癌(DTC)手术切除后单纯T4抑制治疗与131I治疗联合T4抑制治疗的生存率与复发率,证明DTC术后131I治疗的必要性。
6) ~ 131 I therapy
131I治疗
1.
Objective To evaluate the role of the fusion of SPECT/CT images in patients with differentiated thyroid carcinoma (DTC) after ~ 131 I therapy.
目的评价131ISPECT/CT融合图像对于分化型甲状腺癌(DTC)术后患者131I治疗后判断残留和转移病灶的存在和部位以及确定治疗计划的作用。
2.
Methods Using the method of enzyme-linked immunosorbent assay(ELISA) and radioimmunoassay, the levels of sFas in serum and thyroid hormone of GD 52 patients were measured before and after ~ 131 I therapy while 30 healthy subjects with age and sex matched served as controls, and the results were compared with that of the control group.
目的探讨131I治疗对Graves病(GD)患者循环血可溶性细胞凋亡相关蛋白Fas(sFas)的影响。
补充资料：放射性131碘治疗
放射性131碘治疗
一种甲状腺功能亢进症的治疗方法。利用甲状腺高度吸碘的能力和放射性131I放出β射线的生物效应，使甲状腺泡上皮在电离辐射下受到破坏而萎缩。使甲状腺素分泌减少，功能亢进得到控制。一般采用一次空腹口服法，剂量随个体而异。近年来主张小剂量给药，避免出现甲状腺功能低下的不良反应，同时配合抗甲状腺药物治疗，是比较科学的方法。甲状腺功能减退，发生率较高，且逐年增加，本治疗方法主要适用于甲状腺弥漫肿大，年龄在25岁以上，对抗甲状腺药物过敏，长期内科治疗效果不佳；有严重并发症如心力衰竭、心房纤维颤动等不宜手术治疗者。对于妊娠或哺乳妇女、年龄小于20岁者，有严重或活动性肝、肾疾病者；周围血液白细胞总数少于3×109/L，重度甲状腺功能亢进严重突眼患者，不宜做此种治疗。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条